📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 12:24
0 analysed today
FollowTelegram
0
Today
151,433
All-time analysed
43,376
Positive
6,732
Negative
92,513
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Rs 2.88 Cr Net Profit: Smruthi Organics Reports Turnaround in Q1 FY27
Smruthi Organics reported a strong turnaround in Q1 FY27, posting a net profit of Rs 2.88 Cr compared to a net loss of Rs 1.10 Cr in the same quarter last year. Revenue from operations grew 55.4% YoY to Rs 29.30 Cr, driven by the API segment. A significant strategic shift was implemented with the discontinuation of the Formulations Marketing Division effective May 13, 2026, to focus exclusively on APIs and Intermediates. The quarterly profit of Rs 2.88 Cr is nearly equivalent to the company's entire TTM profit of Rs 3 Cr, indicating a sharp recovery in margins.
Confidence: HIGH
What changedThe company has transitioned to a pure-play API manufacturer by discontinuing its Formulations Marketing Division and has successfully turned around from a loss-making quarter to significant profitability.
Why it mattersFor a micro-cap company with a Rs 133 Cr market cap, achieving a quarterly profit nearly equal to its previous full-year TTM profit suggests a potential re-rating if these margins are maintained.
Revenue (Q1 FY27): Rs 29.30 CrNet Profit (Q1 FY27): Rs 2.88 CrYoY Revenue Growth: 55.4%Q1 PAT vs TTM PAT: 96%API Segment Revenue: Rs 29.32 Cr
📅 Short termThe stock may see positive momentum as the market reacts to the sharp turnaround in profitability and the exit from the drag of the formulations business.
📈 Long termThe long-term outlook depends on the company's ability to reach its Rs 150 Cr revenue target and successfully expand into regulated markets while managing Chinese import risks.
⚠ Risk flags
- High product concentration (top 2 products are 50% of revenue)
- Dependency on Chinese imports for raw materials
- High customer concentration (top 10 clients are 70% of sales)
Key Highlights
Revenue from operations increased 55.4% YoY to Rs 29.30 Cr from Rs 18.85 Cr.
Net profit turned positive at Rs 2.88 Cr vs a loss of Rs 1.10 Cr in Q1 FY26.
API segment revenue grew 54.8% YoY to Rs 29.32 Cr, now the sole operating segment.
Earnings Per Share (EPS) improved to Rs 2.51 from a negative Rs 0.96 YoY.
Formulations division discontinued on May 13, 2026, to streamline operations.
👀 What to Watch
Investors should monitor the sustainability of API margins now that the loss-making formulations business has been exited. Key to long-term growth will be the company's ability to diversify its product mix beyond Metformin and Diloxanide Furoate, which currently account for ~50% of revenue.
₹2.88 Cr Net Profit: Smruthi Organics Reports Strong Q1 Turnaround, Discontinues Formulations
Smruthi Organics reported a significant turnaround in Q1 FY27, posting a net profit of ₹2.88 Cr compared to a loss of ₹1.10 Cr in the same quarter last year. Revenue from operations grew 55.4% YoY to ₹29.30 Cr, primarily driven by the API segment. The company has strategically discontinued its loss-making Formulations Marketing Division as of May 14, 2026, to focus exclusively on Bulk Drugs and Intermediates. Notably, this single quarter's profit (₹2.88 Cr) is nearly equal to the company's entire TTM PAT of ₹3 Cr.
Confidence: HIGH
What changedThe company has transitioned to a pure-play API manufacturer by exiting its loss-making formulations business and delivered a sharp recovery in profitability.
Why it mattersThe exit from formulations removes a drag on earnings, while the strong API performance suggests improved scale and asset utilization, which is critical for a micro-cap company with a ₹133 Cr market cap.
Q1 Net Profit: ₹2.88 CrYoY Revenue Growth: 55.4%Q1 PAT vs TTM PAT: 96%API Segment Revenue: ₹29.32 CrFormulations Discontinuance Date: 14-May-2026
📅 Short termThe stock is likely to react positively to the sharp earnings turnaround and the substantial improvement in EPS compared to both YoY and QoQ figures.
📈 Long termThe structural shift to a pure API player could lead to better operational focus, but long-term success depends on reducing high client concentration (70% from top 10) and dependency on Chinese raw materials.
⚠ Risk flags
- High product concentration (top 2 products account for ~50% revenue)
- Dependency on Chinese imports for raw materials
- High customer concentration risk
Key Highlights
Net Profit turned positive at ₹2.88 Cr in Q1 FY27 vs a loss of ₹1.10 Cr in Q1 FY26
Revenue from operations increased 55.4% YoY to ₹29.30 Cr from ₹18.85 Cr
API segment revenue grew to ₹29.32 Cr, representing the company's sole operating segment post-restructuring
Basic EPS improved significantly to ₹2.51 from -₹0.96 in the year-ago period
Formulations division discontinued effective May 14, 2026, to streamline operations and focus on core API strengths
👀 What to Watch
Investors should monitor the sustainability of API margins in the coming quarters and track the company's progress in diversifying its product portfolio beyond its top two molecules to mitigate concentration risk.
₹1.50 Dividend Proposed by Smruthi Organics; AGM Scheduled for August 10, 2026
Smruthi Organics has scheduled its 37th Annual General Meeting for August 10, 2026, to ratify a dividend of ₹1.50 per share (15% on face value). A key agenda item is the redesignation of Ms. Smruthi Eaga as a Whole-time Director with a proposed annual remuneration of ₹84 lakhs, a ~35% increase from her previous pay of ₹62.22 lakhs. The company noted that FY26 profitability was pressured by geopolitical uncertainties and lower sales revenue. To counter this, management is focusing on backward integration and cost optimization at its Hyderabad R&D facility.
Confidence: HIGH
What changedThe company is formalizing its FY26 dividend payment and transitioning a promoter-family director from a non-executive to an executive role.
Why it mattersThe management shift ensures executive continuity within the promoter family, while the dividend provides a yield to shareholders despite a challenging year marked by geopolitical headwinds.
Dividend per share: ₹1.50Proposed Executive Salary: ₹84 lakhs per annumPrevious Executive Salary: ₹62.22 lakhs per annumRecord Date: July 31, 2026Total Equity Shares: 1,14,46,290
📅 Short termThe stock may see minor activity around the July 31 record date for the dividend; the AGM itself is a routine procedural event.
📈 Long termStructural growth depends on the company's ability to improve export realizations and successfully implement cost-saving backward integration.
⚠ Risk flags
- Related-party management (promoter family in key roles)
- Geopolitical risks affecting key export markets
Key Highlights
Dividend of ₹1.50 per share (15%) proposed for 1,14,46,290 equity shares.
Ms. Smruthi Eaga's annual remuneration to increase from ₹62.22 lakhs to ₹84 lakhs.
Record date for dividend eligibility set for July 31, 2026.
AGM to be held via Video Conference on August 10, 2026, at 02:30 p.m.
Company is implementing backward integration to reduce dependence on external raw materials.
👀 What to Watch
Investors should monitor the AGM voting results regarding management remuneration and watch for updates on the execution of backward integration measures intended to improve operating margins.
Smruthi Organics to exit Formulations division; declares ₹1.50 dividend in FY26 Annual Report
Smruthi Organics has released its FY2025-26 Annual Report, proposing a dividend of ₹1.50 per share (15%) with a record date of July 31, 2026. A significant strategic shift was disclosed: the company will undergo a phased wind-down of its Finished Dosage Formulations Division to focus on its core business. Ms. Smruthi Eaga is being elevated to Whole-time Director with a proposed annual salary of ₹84 lakhs. While the formulations exit is a non-adjusting event for FY26, the costs and operational impact will be reflected in FY27 results.
Confidence: HIGH
What changedThe company is exiting its Finished Dosage Formulations segment and transitioning Ms. Smruthi Eaga from a Non-Executive to an Executive Director role.
Why it mattersExiting the formulations segment indicates a strategic pivot to focus resources on the core API/Intermediate business, which may impact short-term revenue but aims for long-term operational efficiency.
Dividend per share: ₹1.50Total equity shares: 1,14,46,290Proposed Executive Salary: ₹84 lakhs per annumRecord Date: July 31, 2026AGM Date: August 10, 2026
📅 Short termThe stock may see routine activity around the dividend record date (July 31) and the AGM (August 10).
📈 Long termThe structural shift to exit formulations and focus on core business will be the primary driver of value over the next 1-2 years.
⚠ Risk flags
- Execution risk in winding down the formulations division
- Potential short-term revenue loss from discontinued operations
- Related-party compensation increase
Key Highlights
Proposed dividend of ₹1.50 per share (15%) on 1,14,46,290 equity shares for FY26.
Strategic decision to discontinue the Finished Dosage Formulations Division to focus on core operations.
Appointment of Ms. Smruthi Eaga as Whole-time Director for 3 years with a salary of ₹84 lakhs per annum.
37th Annual General Meeting (AGM) scheduled for August 10, 2026, via video conferencing.
Record date for dividend eligibility set as July 31, 2026.
👀 What to Watch
Investors should monitor the FY27 financial statements for the impact of the discontinued formulations segment on overall revenue and margins, and track the progress of the core API business.
